GT Biopharma宣布首例患者接受B7-H3靶向NK细胞衔接剂GTB-5550一期临床试验给药

美股速递05-14 20:31

GT Biopharma Inc. 近日宣布，其针对实体瘤的B7-H3靶向自然杀伤（NK）细胞衔接剂GTB-5550，已在第一期临床试验中为首位患者完成给药。

这项试验标志着该公司在开发新型免疫肿瘤疗法方面迈出了关键一步。GTB-5550旨在通过特异性靶向在多种实体瘤中过度表达的B7-H3蛋白，从而激活并引导患者自身的NK细胞攻击肿瘤细胞。

该一期临床试验的主要目标将评估GTB-5550在晚期实体瘤患者中的安全性、耐受性、药代动力学特性以及初步的抗肿瘤活性。公司表示，后续将根据试验进展适时公布更多数据。

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/1183068050?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-05-14 20:31","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1183068050","market":"us","top_or_hot":-1,"title":"GT Biopharma宣布首例患者接受B7-H3靶向NK细胞衔接剂GTB-5550一期临床试验给药","media":"美股速递","content":"<p>GT Biopharma Inc. 近日宣布，其针对实体瘤的B7-H3靶向自然杀伤（NK）细胞衔接剂GTB-5550，已在第一期临床试验中为首位患者完成给药。</p>\n<p>这项试验标志着该公司在开发新型免疫肿瘤疗法方面迈出了关键一步。GTB-5550旨在通过特异性靶向在多种实体瘤中过度表达的B7-H3蛋白，从而激活并引导患者自身的NK细胞攻击肿瘤细胞。</p>\n<p>该一期临床试验的主要目标将评估GTB-5550在晚期实体瘤患者中的安全性、耐受性、药代动力学特性以及初步的抗肿瘤活性。公司表示，后续将根据试验进展适时公布更多数据。</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>GT Biopharma宣布首例患者接受B7-H3靶向NK细胞衔接剂GTB-5550一期临床试验给药</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGT Biopharma宣布首例患者接受B7-H3靶向NK细胞衔接剂GTB-5550一期临床试验给药\n</h2>\n\n<h4 class=\"meta\">\n\n2026-05-14 20:31 北京时间&nbsp;&nbsp;&nbsp;<strong>美股速递</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>GT Biopharma Inc. 近日宣布，其针对实体瘤的B7-H3靶向自然杀伤（NK）细胞衔接剂GTB-5550，已在第一期临床试验中为首位患者完成给药。\n这项试验标志着该公司在开发新型免疫肿瘤疗法方面迈出了关键一步。GTB-5550旨在通过特异性靶向在多种实体瘤中过度表达的B7-H3蛋白，从而激活并引导患者自身的NK细胞攻击肿瘤细胞。\n该一期临床试验的主要目标将评估GTB-5550在晚期实体...</p>\n\n<a href=\"\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"","article_id":"1183068050","we_media_id":"1004306016","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1183068050","pubTimestamp":1778761878,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"美股速递","introduction":"全球快讯第一时间播报","home_visible":1,"id":"1004306016","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"GT Biopharma Inc. 近日宣布，其针对实体瘤的B7-H3靶向自然杀伤（NK）细胞衔接剂GTB-5550，已在第一期临床试验中为首位患者完成给药。\n这项试验标志着该公司在开发新型免疫肿瘤疗法方面迈出了关键一步。GTB-5550旨在通过特异性靶向在多种实体瘤中过度表达的B7-H3蛋白，从而激活并引导患者自身的NK细胞攻击肿瘤细胞。\n该一期临床试验的主要目标将评估GTB-5550在晚期实体瘤患者中的安全性、耐受性、药代动力学特性以及初步的抗肿瘤活性。公司表示，后续将根据试验进展适时公布更多数据。","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK4139":"生物科技","GTBP":"GT Biopharma Inc."},"translate_title":"GT Biopharma Announces First Patient to Receive Phase I Clinical Trial of B7-H3-Targeted NK Cell Engager GTB-5550","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GTBP":1},"content_text":"GT Biopharma Inc. 近日宣布，其针对实体瘤的B7-H3靶向自然杀伤（NK）细胞衔接剂GTB-5550，已在第一期临床试验中为首位患者完成给药。\n这项试验标志着该公司在开发新型免疫肿瘤疗法方面迈出了关键一步。GTB-5550旨在通过特异性靶向在多种实体瘤中过度表达的B7-H3蛋白，从而激活并引导患者自身的NK细胞攻击肿瘤细胞。\n该一期临床试验的主要目标将评估GTB-5550在晚期实体瘤患者中的安全性、耐受性、药代动力学特性以及初步的抗肿瘤活性。公司表示，后续将根据试验进展适时公布更多数据。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":true,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1183068050","isCrawlerRequest":true}